The research team, led by Filippo Biondi and Rosalinda Madonna of the University of Pisa along with collaborators from institutions across Italy, systematically searched PubMed and Scopus databases following the PRISMA 2020 reporting guidelines. The protocol was prospectively registered in PROSPERO, the international registry for systematic review protocols, under registration number CRD420261368392. From the initial search, eight observational studies met the strict inclusion criteria, which required studies to report outcomes of either transcatheter or surgical mitral valve interventions in patients with active or prior cancer. Seven of these studies evaluated M-TEER specifically, and they accounted for the overwhelming majority of patients in the quantitative analysis: 1,522 patients with cancer and 4,716 controls without cancer.

The technical centerpiece of the analysis was the pooling of hazard ratios using random-effects models, the standard statistical approach when studies are expected to differ in their populations and methods. Where hazard ratios were not directly reported by the original studies, the researchers reconstructed them from published survival data using established methods for time-to-event synthesis, including techniques that extract individual-level survival estimates from published Kaplan-Meier curves. This methodological rigor matters because it allowed the team to combine evidence from heterogeneous observational cohorts into a single, statistically coherent estimate of the mortality risk attributable to cancer.

The headline result is unambiguous. In the pooled analysis of M-TEER studies, having cancer was associated with a 72 percent higher risk of all-cause mortality during follow-up, with a hazard ratio of 1.72 and a 95 percent confidence interval of 1.03 to 2.90. The confidence interval, while wide, excludes the null value of 1.0, indicating a statistically significant association. The degree of statistical heterogeneity between studies, measured by the I-squared statistic, was 74.8 percent, which is substantial and signals that the individual studies varied considerably in their populations and effect sizes. Importantly, the association remained consistent across prespecified subgroup and sensitivity analyses, suggesting the finding is not driven by any single outlier study.

What makes the result clinically fascinating is the contrast between short-term and long-term outcomes. The analysis found no significant differences between patients with and without cancer in 30-day mortality or in procedural success, meaning the catheter-based repair itself appears to work equally well in both groups. The clip-based edge-to-edge repair, which approximates the leaflets of the mitral valve using a device delivered through a vein in the leg, is far less invasive than open-heart surgery and has become the treatment of choice for patients deemed too frail or high-risk for conventional surgery. Cancer patients, who often fall precisely into this high-risk category, appear to derive the same immediate procedural benefit as anyone else.

So why do cancer patients die more often in the years that follow? The authors are careful to note that their evidence does not establish the factors responsible for this excess mortality. They outline several plausible mechanisms that future research must disentangle. Frailty, the age-related decline in physiological reserve, is more common in cancer patients and independently predicts death after cardiac procedures. Cardiovascular comorbidity, including pre-existing heart failure and coronary disease, may be more advanced in cancer patients by the time they reach the catheterization laboratory. Treatment-related comorbidity is another candidate: chemotherapy agents such as anthracyclines and targeted therapies like trastuzumab can injure the heart muscle, while chest radiation is a well-established cause of valvular heart disease, stiffening and calcifying the very valves that later require repair. The characteristics of the mitral regurgitation itself, whether it is degenerative or secondary to heart failure, may also differ between the groups, as may other residual confounders that observational data cannot fully adjust for.

One particularly intriguing detail from the analysis is that studies comparing matched cohorts found a non-significant difference in the hazard ratio for long-term mortality. Propensity matching, a statistical technique that pairs cancer patients with non-cancer patients of similar age, comorbidity burden, and valve anatomy, appears to attenuate the mortality signal. This suggests that at least part of the excess risk observed in unmatched analyses may reflect the fact that cancer patients undergoing M-TEER are systematically older, sicker, and more frail than their counterparts, rather than cancer itself being the direct cause of the mortality gap. It is a nuance that will shape how clinicians interpret the headline finding and how they counsel individual patients.

The study also highlights significant gaps in the evidence base. Data on heart failure worsening or hospitalization and on the need for reintervention were insufficient for quantitative synthesis, meaning the analysis could say nothing definitive about whether cancer patients experience more symptomatic recurrence or require more repeat procedures. Only one of the eight included studies assessed surgical mitral valve repair or replacement, so the findings speak almost exclusively to the transcatheter approach. The authors graded the risk of bias in the non-randomized studies using the ROBINS-I tool and the Newcastle-Ottawa Scale, and they are candid that the current evidence is limited by its observational nature and by residual confounding, the ever-present possibility that unmeasured differences between groups explain part of the observed effect.

The context in which this analysis arrives is one of rapidly converging epidemics. Cancer survival has improved dramatically across high-income countries over recent decades, and long-term cancer survivors now number in the tens of millions. Yet cardiovascular disease has emerged as a leading cause of death in this growing population, with several large cohort studies and meta-analyses showing that cardiovascular mortality can rival or even exceed cancer mortality among long-term survivors. Cancer therapies themselves, from anthracycline chemotherapy to mediastinal radiation, accelerate valvular degeneration, myocardial injury, and vascular disease. Valvular heart disease burden has been rising globally, and cardio-oncology, the discipline dedicated to managing the cardiovascular consequences of cancer and its treatment, has been formalized in the 2022 European Society of Cardiology guidelines developed with partner societies across Europe.

For the heart teams that decide between surgery, transcatheter repair, and medical therapy in cancer patients, the new analysis offers both reassurance and caution. The reassurance is that M-TEER can be delivered with equal procedural success and equal short-term safety in patients with cancer, removing one barrier to offering these patients a life-improving intervention. The caution is that the long-term prognosis of these patients remains worse, and the drivers of that excess mortality are unknown. The authors call for prospective cardio-oncology studies designed to improve patient selection and to identify which individuals with cancer are most likely to benefit from transcatheter mitral valve intervention. Until such studies arrive, the clip will keep being deployed, but the question of who truly benefits over the long haul remains open.

Subject of Research: Long-term outcomes of transcatheter mitral valve repair in patients with cancer

Article Title: Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis

Article References: Biondi, F., Cadeddu, C., Camilli, M., Cuomo, A., Mandoli, G. E., Minghini, A., Novo, G., & Madonna, R. (2026). Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis. GeroScience. https://doi.org/10.1007/s11357-026-02539-7

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02539-7

Keywords: cardio-oncology, transcatheter mitral valve repair, M-TEER, mitral regurgitation, cancer patients, meta-analysis, hazard ratio, heart failure, valvular heart disease, procedural success, long-term mortality, GeroScience

The study, part of the ongoing Regensburg Trial on TMVR Techniques in Mitral Regurgitation (RETORT-MR), enrolled 311 patients with severe mitral regurgitation between December 2017 and March 2024. All were considered clinically well compensated before their procedure, meaning they showed no obvious signs of hypervolemia or congestion on physical examination. The researchers calculated each patient’s estimated plasma volume status, or ePVS, a surrogate marker that quantifies the proportional deviation of actual plasma volume from the ideal value. The calculation relies on Hakim’s formula, which derives actual plasma volume from the hematocrit and body weight using sex-dependent constants, and compares it against ideal plasma volume estimates established by Longo and colleagues. Because it requires nothing more than a complete blood count and a scale, the ePVS can be computed in any clinic within minutes, at essentially no cost.

The median ePVS in the cohort was -3.8 percent, with an interquartile range spanning -10.3 to +3.6 percent, indicating that most patients carried slightly less plasma volume than the theoretical ideal. Using receiver operating characteristic analysis anchored to one-year mortality, the investigators identified an optimal cut-off of +0.36 percent for ePVS and 2794 pg/mL for NT-proBNP, the established blood biomarker of myocardial wall stress. Fifty-one patients died during a median follow-up of twelve months, with a median time to death of 422 days. When the cohort was split at these thresholds, the differences in survival were stark and statistically unmistakable.

Patients whose preprocedural ePVS exceeded the cut-off had a Kaplan-Meier estimated mortality of 14.4 percent at one year, compared with just 4.7 percent among those below the threshold. By five years, the gap had widened dramatically: 63.0 percent of patients with elevated ePVS had died, versus 26.0 percent of those with lower values, a difference the log-rank test flagged as highly significant. Elevated NT-proBNP told a similar story, with one-year mortality of 14.6 percent versus 3.5 percent. Crucially, both markers survived multivariable adjustment for competing risk factors. Elevated ePVS carried a hazard ratio of 2.38 for all-cause mortality, while elevated NT-proBNP carried a hazard ratio of 4.30, confirming that each independently predicted death after the procedure.

Perhaps the most striking finding emerged when the two biomarkers were combined into a single trichotomous congestion variable. Patients with both markers above their cut-offs faced a hazard ratio of 14.27 for mortality compared with those in whom neither was elevated, a nearly fifteen-fold increase in risk. Even one elevated marker alone conferred a hazard ratio of 6.67. Kaplan-Meier curves for the three groups separated in a clean, stepwise fashion, with one-year mortality climbing from 1.9 percent in the double-negative group to 8.2 percent with one marker elevated and 21.5 percent with both. Five-year mortality followed the same gradient, reaching 64.8 percent in the doubly elevated group. The authors argue this reflects the integration of two fundamentally different congestion phenotypes into one comprehensive risk picture.

That pathophysiological distinction is central to the study’s significance. NT-proBNP is released by cardiac muscle cells in response to end-diastolic wall stress caused by pressure or volume overload inside the heart, and it is tightly linked to cardiac function. In this cohort, patients with elevated NT-proBNP indeed showed the expected signature of advanced myocardial disease: a higher prevalence of heart failure with reduced ejection fraction, lower left ventricular ejection fractions, reduced tricuspid annular plane systolic excursion, and more frequent secondary mitral regurgitation. Elevated ePVS, by contrast, was not associated with impaired systolic function. Instead, it marked a composite phenotype dominated by intravascular volume expansion, hemodilution, renal dysfunction, and systemic congestion. Patients with high ePVS were slightly older, had significantly lower estimated glomerular filtration rates, lower body mass index, lower hemoglobin and hematocrit, and required higher doses of loop diuretics.

A critical methodological question was whether ePVS simply repackages anemia, which is itself a known predictor of poor outcomes in heart failure. Because hematocrit is a direct component of the ePVS formula, the researchers built nested multivariable Cox models comparing ePVS against hematocrit, both as a continuous variable and as a sex-specific dichotomized variable. The results were decisive: hematocrit alone was not independently associated with mortality and did not improve model fit, whereas ePVS remained significant even when hematocrit was included, and adding ePVS significantly improved model fit in likelihood-ratio tests. Time-dependent reclassification analyses using integrated discrimination improvement showed that ePVS added significant prognostic information at a two-year horizon. This suggests the prognostic power lies not in anemia itself but in the multifactorial processes of plasma volume expansion and pseudoanemia that ePVS captures.

The findings held across both major etiologies of mitral regurgitation. In patients with primary, or degenerative, mitral regurgitation, elevated ePVS carried a univariable hazard ratio of 6.26, while in those with secondary or mixed disease the hazard ratio was 2.95, both statistically significant. The combined ePVS and NT-proBNP variable also stratified mortality in both subgroups. Regarding cardiovascular death specifically, of the 51 total deaths, 26 were cardiovascular in origin, and elevated ePVS maintained its independent association with cardiovascular mortality in multivariable models, with a hazard ratio of 2.66. Interestingly, only NT-proBNP, not ePVS alone, predicted rehospitalization for heart failure, which the authors interpret as evidence that ePVS marks a subtler, subclinical form of congestion that drives progressive organ dysfunction and death rather than acute decompensation requiring readmission.

The clinical implications are considerable. M-TEER candidates are a heterogeneous, high-risk population in whom traditional risk assessment has struggled to identify who will benefit most and who will deteriorate despite a technically successful procedure. The study found that, alongside the biomarkers, only a reduced left ventricular ejection fraction, severe preprocedural tricuspid regurgitation, and severe residual mitral regurgitation after the procedure remained independently associated with mortality, underscoring that optimal heart failure therapy and excellent procedural results remain essential. But the ePVS offers something those measures do not: a zero-cost, universally available window into subclinical intravascular congestion in patients who appear clinically dry. The authors caution that the estimated plasma volume depends on multiple variables and provides only limited information about true quantitative plasma volume, so it should not dictate therapy on its own.

Limitations temper the enthusiasm appropriately. RETORT-MR is a single-center study with a relatively small cohort, a low absolute number of deaths, and a substantial proportion of patients lost to follow-up, all of which constrain statistical power, particularly for the reclassification analyses and cause-specific mortality. The authors themselves emphasize that the results warrant validation in larger cohorts with more adverse events. Nevertheless, the consistency of the signal across etiologies, its independence from hematocrit and established covariates, and the sheer magnitude of the combined-marker hazard ratio make a compelling case. If confirmed, a calculation performable from a routine blood draw could become a standard element of preprocedural evaluation, flagging the silent fluid overload that today’s stethoscopes cannot hear and tomorrow’s outcomes depend on.

Subject of Research: Prognostic value of estimated plasma volume status in patients undergoing transcatheter edge-to-edge mitral valve repair

Article Title: The estimated plasma volume status is an independent predictor for mortality in patients undergoing transcatheter mitral valve repair

Article References: The estimated plasma volume status is an independent predictor for mortality in patients undergoing transcatheter mitral valve repair. (n.d.). https://doi.org/10.1007/s00392-026-03021-2

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03021-2

Keywords: M-TEER, mitral regurgitation, ePVS, NT-proBNP, congestion, heart failure, plasma volume status, mortality prediction, biomarkers, transcatheter valve repair, risk stratification, cardiology